Delcath Systems, Inc. (DCTH)
Largest Insider Buys in Sector
DCTH Stock Price History Chart
DCTH Stock Performance
About Delcath Systems, Inc.
Delcath Systems, Inc., an interventional oncology company, focuses on the treatment of primary and metastatic liver cancers in the United States and Europe. The company's lead product candidate is HEPZATO KIT, a melphalan for injection/hepatic delivery system to administer high-dose chemotherapy to the liver while controlling systemic exposure and associated side effects. Its clinical development program for HEPZATO is the FOCUS clinical trial for patients with metastatic hepatic dominant Uveal Melanoma to investigate objective response rate in …
Insider Activity of Delcath Systems, Inc.
Over the last 12 months, insiders at Delcath Systems, Inc. have bought $981,272 and sold $0 worth of Delcath Systems, Inc. stock.
On average, over the past 5 years, insiders at Delcath Systems, Inc. have bought $775,922 and sold $0 worth of stock each year.
Highest buying activity among insiders over the last 12 months: Vukovic Vojo (Chief Medical Officer) — $806,400. Rosalind Advisors, Inc. (director) — $240,410. MICHEL GERARD J (Chief Executive Officer) — $199,920.
The last purchase of 26,882 shares for transaction amount of $100,001 was made by SALAMON STEVEN A J (director) on 2024‑03‑19.
List of Insider Buy and Sell Transactions, Delcath Systems, Inc.
| 2024-03-19 | director | 26,882 0.106% | $3.72 | $100,001 | +83.76% | |||
| 2024-03-19 | director | 26,882 0.106% | $3.72 | $100,001 | +83.76% | |||
| 2023-12-12 | Chief Medical Officer | 40,000 0.1728% | $3.00 | $120,000 | +76.71% | |||
| 2023-12-08 | Chief Executive Officer | 34,000 0.1516% | $2.94 | $99,960 | +85.78% | |||
| 2023-11-17 | director | 100,000 0.6437% | $2.40 | $240,410 | +115.23% | |||
| 2023-11-17 | SVP of Finance, PFO and PAO | 30,000 0.1952% | $2.43 | $72,900 | +115.23% | |||
| 2023-11-16 | Chief Medical Officer | 60,000 0.3928% | $2.48 | $148,800 | +110.53% | |||
| 2023-11-16 | See Remarks | 40,000 0.2618% | $2.48 | $99,200 | +110.53% | |||
| 2023-10-13 | Chief Operating Officer | 14,505 0.0944% | $3.44 | $49,897 | +36.99% | |||
| 2023-08-21 | director | 10,550 0.093% | $4.80 | $50,640 | -11.42% | |||
| 2023-03-29 | Chief Executive Officer | 19,646 0.0001% | $4.84 | $95,087 | -19.95% | |||
| 2022-12-14 | director | 15,215 0.1678% | $3.62 | $55,045 | +26.22% | |||
| 2022-12-14 | director | 15,215 0.1678% | $3.62 | $55,045 | +26.22% | |||
| 2022-12-13 | Chief Executive Officer | 51,725 0.4573% | $2.90 | $150,003 | +26.22% | |||
| 2022-07-20 | Chief Executive Officer | 62,814 0.6782% | $3.98 | $250,000 | +7.50% | |||
| 2022-05-16 | Chief Operating Officer | 3,300 0.0396% | $4.61 | $15,213 | -13.01% | |||
| 2022-05-13 | 5,000 0.0635% | $5.03 | $25,135 | -15.89% | ||||
| 2022-05-12 | 6,000 0.0764% | $4.90 | $29,424 | -13.19% | ||||
| 2022-04-19 | 1,600 0.0191% | $6.25 | $10,000 | -36.05% | ||||
| 2022-04-19 | 1,600 0.0191% | $6.25 | $10,000 | -36.05% |
Insider Historical Profitability
| SALAMON STEVEN A J | director | 1121025 4.0035% | $10.93 | 14 | 0 | <0.0001% |
| Aharon Gil | director | 1069710 3.8203% | $10.93 | 3 | 0 | <0.0001% |
| Rosalind Advisors, Inc. | director | 1038828 3.71% | $10.93 | 12 | 0 | <0.0001% |
| MICHEL GERARD J | Chief Executive Officer | 262345 0.9369% | $10.93 | 11 | 0 | <0.0001% |
| Vukovic Vojo | Chief Medical Officer | 100000 0.3571% | $10.93 | 2 | 0 |
Institutional Investor Ownership
| Aigh Capital Management Llc | $11.09M | 8.49 | 2.36M | +99.61% | +$5.54M | 6.34 | |
| Vivo Capital | $7.95M | 6 | 1.67M | +94.9% | +$3.87M | 0.69 | |
| Bvf Inc Il | $5.73M | 4.33 | 1.2M | +23.14% | +$1.08M | 0.04 | |
| The Vanguard Group | $3.26M | 2.46 | 683,686 | +30.97% | +$771,204.01 | <0.0001 | |
| CIBC World Markets | $1.24M | 0.94 | 260,280 | -0.44% | -$5,482.78 | <0.01 |